Date: August 18, 2021 Your Name: Yang Liu Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4    Consulting fees   XNone      5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events   XNone      6    Payment for expert   XNone	
lectures, presentations,	
lectures, presentations,	
lectures, presentations,	
speakers bureaus, manuscript writing or educational events	
manuscript writing or educational events	
educational events	
testimony	
7 Support for attendingXNone	
meetings and/or travel	
8 Patents planned, issued or X_None	
pending	
9 Participation on a DataXNone	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role X_None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11  Stock or stock options XNone	
12 Receipt of equipment, <u>X_None</u>	
materials, drugs, medical writing, gifts or other	
services	
13 Other financial or non- X None	
financial interests	

Chia-tai Tianging Pharmaceutical Group Co., Ltd provided the study drug.

Please place an "X" next to the following statement to indicate your agreement:

Date: August 26, 2021 Your Name: Ying Cheng Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	X N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	V None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Kai Li Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	X N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	V None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Jianhua Shi Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
_		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	X N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	V None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Ying Liu Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	Y None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Lin Wu Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
_		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	V None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Baohui Han Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	X N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	V None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12		X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Gongyan Chen Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
_		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	X N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	Y None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12		X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Jianxing He Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	V None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12		X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Jie Wang Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ũ	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
0	pending		
	P		
9	Participation on a Data	X None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12		X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Haifeng Qin Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	Y None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12		X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Xiaoling Li Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
_		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	X N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	V None	
/	meetings and/or travel	XNone	
	Ū I		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12		X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 18, 2021 Your Name: Masatsugu Hamaji Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None Chia-tai Tianqing Pharmaceutical Group Co., Ltd	provided the study drug		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone			
3	Royalties or licenses	XNone			

4    Consulting fees				
lectures, presentations, speakers bureaus, manuscript writing or educational events	4	Consulting fees	XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events    X_None      6    Payment for expert testimony    X_None      7    Support for attending meetings and/or travel   X_None      8    Patents planned, issued or pending   X_None      9    Patents planned, issued or Advisory Board   X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   X_None      11    Stock or stock options   X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   X_None      13    Other financial or non-   X_None	5	-	XNone	
manuscript writing or educational events   X_None      6    Payment for expert testimony   X_None      7    Support for attending meetings and/or travel   X_None      7    Support for attending meetings and/or travel   X_None      8    Patents planned, issued or pending   X_None      9    Patticipation on a Data Safety Monitoring Board or Advisory Board   X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   X_None      11    Stock or stock options   X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   X_None      13    Other financial or non-   X_None				
educational events				
6    Payment for expert testimony   X_None      7    Support for attending meetings and/or travel   X_None      7    Support for attending meetings and/or travel   X_None      8    Patents planned, issued or pending   X_None      9    Patricipation on a Data Safety Monitoring Board or Advisory Board   X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   X_None      11    Stock or stock options   X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   X_None      13    Other financial or non-   X_None				
testimony	6		V. Nere	
7    Support for attending meetings and/or travel   X_None      8    Patents planned, issued or pending   X_None      9    Participation on a Data Safety Monitoring Board or Advisory Board   X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   X_None      11    Stock or stock options   X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   X_None      13    Other financial or non-   X_None	6		XNone	
meetings and/or travel  Image: Construction of travel    pending  Image: Construction of travel    meetings and/or travel  Image: Construction of travel    pending  Image: Construction of travel    materials, drugs, medical writing, gifts or other services  Image: Construction on on-service    materials, drugs, medical writing, gifts or other services  Image: Construction on-service    materials or non-  Image: Construction on-service		testimony		
meetings and/or travel  Image: Construction of travel    pending  Image: Construction of travel    meetings and/or travel  Image: Construction of travel    pending  Image: Construction of travel    materials, drugs, medical writing, gifts or other services  Image: Construction on on-service    materials, drugs, medical writing, gifts or other services  Image: Construction on-service    materials or non-  Image: Construction on-service	7	Support for attending	Y None	
8  Patents planned, issued or pending	'			
pending				
pending				
pending				
9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   XNone      13    Other financial or non-   XNone	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board    Image: Construction of Monitoring Board or Advisory Board    Image: Construction of Monitoring Board or Advisory Board      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   X_None      11    Stock or stock options   X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   X_None      13    Other financial or non-   X_None		pending		
Safety Monitoring Board or Advisory Board    Image: Construction of Monitoring Board or Advisory Board    Image: Construction of Monitoring Board or Advisory Board      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   X_None      11    Stock or stock options   X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   X_None      13    Other financial or non-   X_None				
Advisory Board	9	-	XNone	
10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   X_None      11    Stock or stock options   X_None      11    Stock or stock options   X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services   X_None      13    Other financial or non-   X_None				
in other board, society, committee or advocacy group, paid or unpaid		-		
committee or advocacy	10		XNone	
group, paid or unpaid				
11    Stock or stock options   X_None				
12  Receipt of equipment, materials, drugs, medical writing, gifts or other services X_None    13  Other financial or non- X_None				
materials, drugs, medical writing, gifts or other services	11	Stock or stock options	XNone	
materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services	12	Receipt of equipment	X None	
writing, gifts or other services	12			
services  13  Other financial or non-  _X_None				
	13		X None	

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

# Please place an "X" next to the following statement to indicate your agreement:

Date: August 26, 2021 Your Name: Henry S. Park Manuscript Title: Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial Manuscript number (if known): TLCR-21-632

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	Chia-tai Tianqing	provided the study drug
	provision of study materials,	Pharmaceutical Group Co.,	
	medical writing, article	Ltd	
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Food and Drug	Payments made to institution (Research grant)
	any entity (if not indicated	Administration	
	in item #1 above).		
3	Royalties or licenses	X None	

4	Consulting fees	AstraZeneca	Payments made to me
		Guidepoint	Payments made to me
		Grand Rounds Health	Payments made to me
5	Payment or honoraria for	Bristol Myers Squibb	Payments made to me
	lectures, presentations,	Varian Medical Systems	Payments made to me
	speakers bureaus,	Rad Onc Questions	Payments made to me
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	Varian Medical Systems	Payments made to me
	meetings and/or travel		
-			
8	Patents planned, issued or	X None	
	pending		
0	Deuticia eticar e Dete	V. Novo	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Henry S. Park receives research grant from U.S. FDA, consulting fees from AstraZeneca, Guidepoint and Grand Rounds Health, payments from Bristol Myers Squibb, Varian Medical Systems, Rad Onc Questions, and support for attending meeting from Varian Medical Systems.

Chia-tai Tianqing Pharmaceutical Group Co., Ltd provided the study drug.

Please place an "X" next to the following statement to indicate your agreement: